Please login to the form below

Not currently logged in
Email:
Password:

CGRP

This page shows the latest CGRP news and features for those working in and with pharma, biotech and healthcare.

Allergan gets FDA nod for first oral CGRP drug for migraine

Allergan gets FDA nod for first oral CGRP drug for migraine

The CGRP inhibitors offer hope to patients with acute migraine who can't get relief from the current array of therapies, which consists of pain-killing drugs and triptans. ... Meanwhile, Allergan also has an oral CGRP inhibitor in late-stage development

Latest news

  • Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

    Eptinezumab is one of the new migraine prevention drugs in the CGRP inhibitor class, but unlike already-marketed rivals from Amgen/Novartis, Eli Lilly and Teva, it is delivered intravenously rather ... Lundbeck clearly agrees, saying the drug provides

  • New efficacy data boosts Aimovig’s migraine market lead New efficacy data boosts Aimovig’s migraine market lead

    The results from the STRIVE trial are good news for Novartis and its co-marketer Amgen, who have established Aimovig (erenumab) as the leader in the new class of CGRP inhibitor ... These results expand the potential scope of Aimovig’s use, and will

  • AbbVie CEO Gonzalez defends Allergan takeover AbbVie CEO Gonzalez defends Allergan takeover

    For AbbVie, Allergan’s most interesting programmes are a clutch central nervous system (CNS) candidates including antidepressant Vraylar (cariprazine) – which it says has blockbuster potential – as well as oral CGRP inhibitors

  • Lilly claims cluster headache first for CGRP drug Emgality Lilly claims cluster headache first for CGRP drug Emgality

    Competition fierce in new class. Eli Lilly has pushed its nose in front of its rivals in the CGRP inhibitor market with the first FDA approval of a drug in the ... It’s not only the first of the new CGRP inhibitor class to be approved for the condition,

  • Pricing pressures peg back Lilly’s growth products Pricing pressures peg back Lilly’s growth products

    Lilly has other new medicines rolling out to help it manage the Cialis patent cliff, and third-to-market CGRP inhibitor for migraine – Emgality (galcanezumab) - added $14m in the quarter, overtaking

More from news
Approximately 5 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Licence. 217. Teva Pharmaceuticals/ Alder Biopharmaceuticals. Patents covering anti-calcitonin gene-related peptide (CGRP) antibodies and methods - eptinezumab (p3). † ... licence agreement in January with respect to calcitonin gene-related peptide

  • The good, the bad and the ugly The good, the bad and the ugly

    Three CGRP monoclonal antibodies will launch in the US for migraine in 2018 - with a fourth anticipated in 2019.

  • Deal Watch November 2015 Deal Watch November 2015

    455. Heptares. Teva. Licence drug-discovery agreement. Small molecule calcitonin gene-related peptide (CGRP) antagonists for migraine.

  • Pharma deals in July 2015 Pharma deals in July 2015

    related peptide (CGRP) receptor antagonist programme with the lead product at the end of phase II for treatment of migraine. ... 293. Merck / Allergan. Acquisition of R&D. Oral CGRP compounds (lead Phase 2) for migraine.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    3, 850. Labrys Biologics/ Teva. Company acquisition. Includes Labrys' p2b anti-CGRP mAb for treatment of episodic migraine.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics